It has been suggested that an mTOR inhibitor may act synergistically with fasting to inhibit CRC proliferation via Farnesyl-Diphosphate Farnesyltransferase 1 (FDFT1)-mediated AKT/mTOR/HIF1α pathway inhibition [149]. Here, AKT1 is linked to colorectal carcinoma.